ADMA Biologics, Inc. (ADMA)
Total Valuation
ADMA Biologics has a market cap or net worth of $1.54 billion. The enterprise value is $1.62 billion.
Market Cap | 1.54B |
Enterprise Value | 1.62B |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024, after market close.
Earnings Date | May 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 228.22 million shares outstanding. The number of shares has increased by 13.19% in one year.
Shares Outstanding | 228.22M |
Shares Change (YoY) | +13.19% |
Shares Change (QoQ) | -3.32% |
Owned by Insiders (%) | 2.50% |
Owned by Institutions (%) | 77.29% |
Float | 223.86M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 20.98 |
PS Ratio | 5.96 |
Forward PS | 4.52 |
PB Ratio | 11.38 |
P/FCF Ratio | 381.78 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 316.11, with an EV/FCF ratio of 401.71.
EV / Earnings | n/a |
EV / Sales | 6.27 |
EV / EBITDA | 316.11 |
EV / EBIT | n/a |
EV / FCF | 401.71 |
Financial Position
The company has a current ratio of 5.16, with a Debt / Equity ratio of 0.97.
Current Ratio | 5.16 |
Quick Ratio | 1.58 |
Debt / Equity | 0.97 |
Debt / EBITDA | 25.71 |
Debt / FCF | 32.67 |
Interest Coverage | -0.13 |
Financial Efficiency
Return on equity (ROE) is -19.50%.
Return on Equity (ROE) | -19.50% |
Return on Assets (ROA) | -8.30% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | $413,806 |
Profits Per Employee | -$45,255 |
Employee Count | 624 |
Asset Turnover | 0.76 |
Inventory Turnover | 1.01 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +103.01% in the last 52 weeks. The beta is 0.43, so ADMA Biologics's price volatility has been lower than the market average.
Beta (1Y) | 0.43 |
52-Week Price Change | +103.01% |
50-Day Moving Average | 5.58 |
200-Day Moving Average | 4.28 |
Relative Strength Index (RSI) | 72.95 |
Average Volume (30 Days) | 2,755,036 |
Short Selling Information
The latest short interest is 7.99 million, so 3.50% of the outstanding shares have been sold short.
Short Interest | 7.99M |
Short Previous Month | 6.72M |
Short % of Shares Out | 3.50% |
Short % of Float | 3.57% |
Short Ratio (days to cover) | 3.05 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $258.22 million and -$28.24 million in losses. Loss per share was -$0.13.
Revenue | 258.22M |
Gross Profit | 88.94M |
Operating Income | 21.63M |
Pretax Income | -28.24M |
Net Income | -28.24M |
EBITDA | 5.12M |
EBIT | -3.21M |
Loss Per Share | -$0.13 |
Balance Sheet
The company has $51.35 million in cash and $131.64 million in debt, giving a net cash position of -$80.29 million or -$0.35 per share.
Cash & Cash Equivalents | 51.35M |
Total Debt | 131.64M |
Net Cash | -80.29M |
Net Cash Per Share | -$0.35 |
Equity / Book Value | 135.21M |
Book Value Per Share | 0.59 |
Working Capital | 207.21M |
Cash Flow
In the last 12 months, operating cash flow was $8.80 million and capital expenditures -$4.77 million, giving a free cash flow of $4.03 million.
Operating Cash Flow | 8.80M |
Capital Expenditures | -4.77M |
Free Cash Flow | 4.03M |
FCF Per Share | $0.02 |
Margins
Gross margin is 34.44%, with operating and profit margins of 8.38% and -10.94%.
Gross Margin | 34.44% |
Operating Margin | 8.38% |
Pretax Margin | -10.94% |
Profit Margin | -10.94% |
EBITDA Margin | 1.98% |
EBIT Margin | -1.24% |
FCF Margin | 1.56% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -13.19% |
Shareholder Yield | -13.19% |
Earnings Yield | -1.84% |
FCF Yield | 0.26% |
Analyst Forecast
The average price target for ADMA Biologics is $7.88, which is 16.91% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $7.88 |
Price Target Difference | 16.91% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | 10.81% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 4.11 and a Piotroski F-Score of 5.
Altman Z-Score | 4.11 |
Piotroski F-Score | 5 |